SEC Probes Teva Over Possible FCPA Violations in Latin America

Washington Drug Letter
A A
Teva Pharmaceuticals is the target of an SEC bribery investigation and has been handed a subpoena for documents related to its compliance with the Foreign Corrupt Practice Act (FCPA) in Latin America.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00